Aurobindo Pharma Rs 800 Cr Buyback Opens Apr 23

New Delhi:  Aurobindo Pharma Ltd on Tuesday said it has set April 23 as the opening date for its Rs 800 crore buyback offer.

The closing date for the buyback is April 29, Aurobindo Pharma said in a regulatory filing.

Earlier on April 6, the company’s board had approved buyback of up to 54,23,728 fully paid-up equity shares having a face value of Re 1 each at a price of Rs 1,475 per share for an aggregate amount up to Rs 800 crore on a proportionate basis through the tender offer route.

The company has set April 17 as the record date for determining the entitlement and the names of equity shareholders who would be eligible to participate in the buyback.

The buyback size constitutes 3.93 per cent and 2.62 per cent of the aggregate of the total paid-up equity share capital and free reserves (including securities premium) of the company as per the audited standalone and consolidated financial statements of the Company as at March 31, 2025, respectively, the filing said.

In its letter to shareholders, Aurobindo Pharma said the buyback will help it reward shareholders and enhance the overall return to them, while it is expected to improve earnings per share and other key ratios such as return on net worth and return on assets over a period of time.

The buyback will not result in a change in control or otherwise affect the existing management structure of the company, it added.

Related Posts

AB-PMJAY Crackdown: 2,359 Hospitals De-empanelled, 1,200 Suspended for Violating Scheme Guidelines, Nadda Tells Lok Sabha

New Delhi: The Centre has disclosed a significant enforcement action against hospitals found violating the guidelines of the Ayushman Bharat–Pradhan Mantri Jan Arogya Yojana (AB-PMJAY), with 2,359 hospitals de-empanelled, 1,200…

NHS backs delayed‑release treatment for cystinosis

Decision expands options for eligible patients NHS England has recommended delayed‑release mercaptamine bitartrate for routine commissioning for eligible patients aged one year and above with nephropathic cystinosis. The decision provides…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

AB-PMJAY Crackdown: 2,359 Hospitals De-empanelled, 1,200 Suspended for Violating Scheme Guidelines, Nadda Tells Lok Sabha

AB-PMJAY Crackdown: 2,359 Hospitals De-empanelled, 1,200 Suspended for Violating Scheme Guidelines, Nadda Tells Lok Sabha

NHS backs delayed‑release treatment for cystinosis

NHS backs delayed‑release treatment for cystinosis

Promotion of Drug Inspectors (Medical Devices) raises hopes of Effective Regulation & Patient Safety

Promotion of Drug Inspectors (Medical Devices) raises hopes of Effective Regulation & Patient Safety

Maharashtra FDA Permanently Cancels Licence of Pune Ayurvedic Drug Manufacturer Over Serious GMP and Quality Violations

Maharashtra FDA Permanently Cancels Licence of Pune Ayurvedic Drug Manufacturer Over Serious GMP and Quality Violations

Telangana DCA Seizes Gabapentin Tablets Falsely Sold as Nutraceuticals in Hyderabad

Telangana DCA Seizes Gabapentin Tablets Falsely Sold as Nutraceuticals in Hyderabad

Massive Blood Wastage in Gujarat: Over 85,000 Units Discarded Due to Storage Lapses and Expiry

Massive Blood Wastage in Gujarat: Over 85,000 Units Discarded Due to Storage Lapses and Expiry